Pharmacokinetics of recombinant interferon-alpha 2 (rIFN-alpha 2) following intralesional administration into patients with malignant gliomas was investigated. A dose of 5 X 10(6) IU of rIFN-alpha 2 was injected locally postoperatively for 2 weeks each day, and the same dose was then given once a week for 10 additional weeks. During the daily and weekly administration, the IFN was consistently present in the fluid of the postsurgical cavity. Not until 5 weeks after the end of the IFN administration was the IFN undetectable. The decay of IFN injected was minimal.
Pharmacokinetics of recombinant interferon-alpha 2 following intralesional administration in malignant glioma patients / Maleci, A; Antonelli, Guido; Guidetti, B; Dianzani, F.. - In: JOURNAL OF INTERFERON RESEARCH. - ISSN 0197-8357. - STAMPA. - 7:(1987), pp. 107-109. [10.1089/jir.1987.7.107]
Pharmacokinetics of recombinant interferon-alpha 2 following intralesional administration in malignant glioma patients.
ANTONELLI, Guido;
1987
Abstract
Pharmacokinetics of recombinant interferon-alpha 2 (rIFN-alpha 2) following intralesional administration into patients with malignant gliomas was investigated. A dose of 5 X 10(6) IU of rIFN-alpha 2 was injected locally postoperatively for 2 weeks each day, and the same dose was then given once a week for 10 additional weeks. During the daily and weekly administration, the IFN was consistently present in the fluid of the postsurgical cavity. Not until 5 weeks after the end of the IFN administration was the IFN undetectable. The decay of IFN injected was minimal.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
